Reproductive and Genetic Hospital of CITIC-Xiangya, Changsha, China.
NHC Key Laboratory of Human Reproductive and Stem Cell Engineering, Changsha, China.
BMC Pregnancy Childbirth. 2023 Mar 22;23(1):199. doi: 10.1186/s12884-023-05512-w.
To evaluate the clinical availability and stability of histological endometrial dating as a tool for personalized frozen-thawed embryo transfer (pFET) in patients with repeated implantation failure (RIF) in natural cycles.
A total of 1245 RIF patients were recruited to the present study. All of the patients received an endometrial dating evaluation on day 7 post-ovulation (PO + 7) to guide their first pFET. The second and third pFETs were executed according to histological examination (again employing biopsy) or by reference to previous results. Subsequent pregnancy outcomes for all of the cycles were ultimately tracked.
The out-of-phase rate for RIF patients was 32.4% (404/1245) and the expected dating rate (the probability of the expected endometrial dating aligning with repeat biopsy) for endometrial dating reevaluation was as high as 94.3% (50/53). The clinical pregnancy rates of first, second, and third pFETs were 65.3%, 50.0%, and 44.4%, respectively; and the cumulative clinical pregnancy rate attained 74.9% after three transfers. Endometrial dating reevaluations met expectations with more than a 2-year duration in three cases and elicited favorable clinical outcomes.
We validated the relatively high stability of the histological endometrial dating platform-including the out-of-phase rate and the expected dating rate of reevaluation in patients with RIF-by expanding the sample size. The pFET, based on histological endometrial dating, was of acceptable clinical value and was worthy of promotion in patients with unexplained RIF.
评估组织学子宫内膜分期作为反复着床失败(RIF)患者自然周期冻融胚胎移植(pFET)个体化工具的临床可用性和稳定性。
本研究共纳入 1245 例 RIF 患者。所有患者均在排卵后第 7 天(PO+7)进行子宫内膜分期评估,以指导首次 pFET。第二次和第三次 pFET 根据组织学检查(再次进行活检)或参考既往结果进行。最终跟踪所有周期的后续妊娠结局。
RIF 患者的不同时相率为 32.4%(404/1245),子宫内膜分期重新评估的预期分期率(预期子宫内膜分期与重复活检一致的概率)高达 94.3%(50/53)。首次、第二次和第三次 pFET 的临床妊娠率分别为 65.3%、50.0%和 44.4%;三次移植后的累积临床妊娠率达到 74.9%。在三个病例中,子宫内膜分期重新评估的预期超过 2 年,并且产生了良好的临床结局。
通过扩大样本量,我们验证了组织学子宫内膜分期平台在 RIF 患者中的相对较高的稳定性,包括不同时相率和重新评估的预期分期率。基于组织学子宫内膜分期的 pFET 具有可接受的临床价值,值得在不明原因 RIF 患者中推广。